Clinical trials: Genital Infection
HIV Infections
Effect of Leflunomide on T Cell Proliferation in HIV-Infected Patients
This study will evaluate the effect of leflunomide on the life cycle of a specific immune cell called CD4+ T cell in HIV-infected patients.
- Trial name
- NCT00101374
- Testing
- Leflunomide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Papilloma Virus, Hiv
Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV.
The Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living with HIV: A Prospective, Individual, Double-Blind, Randomized Controlled Study is evaluating immediate or delayed single-dose…
- Trial name
- HOPE II (NCT06436274)
- Testing
- GARDASIL®9, Menveo®/Menactra®
- Where
- 3 sites in Botswana, Rwanda and 1 more
- Volunteers
- 778 people
- Sponsor
- Massachusetts General Hospital
Infection, Human Immunodeficiency Virus
Efficacy and Safety of the ACC017-Based Antiretroviral Regimen in Treatment-Experienced Adults With HIV-1 Harboring Non-Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations
This trial is a randomized, double-blind, placebo-controlled clinical study conducted in treatment-experienced adults with NNRTI-resistant HIV-1, designed to preliminarily evaluate the efficacy, safety, and resistance profile of…
- Trial name
- NCT07711210
- Testing
- ACC017
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Jiangsu Aidea Pharmaceutical Group Co., Ltd.
Cervical Carcinoma, Human Papillomavirus Infection
Multilevel HPV Self-Testing Intervention for the Increase of Cervical Cancer Screening Among Women in Appalachia
This trial studies how well a multilevel human papillomavirus (HPV) self-testing intervention works in increasing cervical cancer screening among women in Appalachia.
- Trial name
- NCT04411849
- Testing
- Best Practice, HPV Self-Collection, Informational Intervention
- Where
- 4 sites in United States
- Volunteers
- 802 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Acute Hepatitis C, HIV
The Natural History and Treatment of Acute Hepatitis C Virus (HCV) in HIV-positive Individuals
The aim of the study is to investigate the epidemiology, natural history and treatment outcomes of acute hepatitis C (HCV) infection.
- Trial name
- PROBE-C (NCT01289652)
- Where
- Germany
- Volunteers
- 600 people
- Sponsor
- Benedetta Mattioli
Human Immunodeficiency Virus
Study of the Safety, Tolerability and Pharmacokinetics of TMB-607 in HIV-Negative Volunteers
The study is a Phase 1, randomized, double-blinded, placebo-controlled, sequential single dose escalation safety, tolerability and pharmacokinetic study of subcutaneous and intramuscular TMB-607 administered to HIV-negative…
- Trial name
- NCT03110549
- Testing
- TMB-607
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- TaiMed Biologics Inc.
HIV-1 Infection, HIV Infections
Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1
The objective of this study is to evaluate the safety and efficacy of a novel combination antiretroviral therapy regimen consisting of maraviroc plus darunavir/ritonavir in treatment-naive patients infected with R5-tropic HIV-1.
- Trial name
- MIDAS (NCT00993148)
- Testing
- maraviroc, darunavir, ritonavir
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Northwestern University
Genital Herpes
Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes
The aim of the study is to evaluate the safety and efficacy of "AIC316 (pritelivir)" 100 mg once daily compared to valacyclovir 500 mg once daily for the prevention of HSV-2 genital shedding.
- Trial name
- NCT01658826
- Testing
- AIC316, Valacyclovir
- Where
- 4 sites in United States
- Volunteers
- 91 people
- Sponsor
- AiCuris Anti-infective Cures AG
Human Papilloma Virus, Cervical Cancer
Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)
This study will examine the safety and tolerability of octavalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) vaccine formulated with amorphous aluminum hydroxysulfate (AAHS) and ISCOMATRIX™ (IMX).
- Conditions
- Human Papilloma Virus, Cervical Cancer, Vulvar Cancer, Vaginal Cancer
- Trial name
- NCT00851643
- Testing
- Octavalent HPV with 15 mcg IMX / AAHS, Octavalent HPV with 30 mcg IMX / AAHS, Octavalent HPV with 60 mcg IMX / AAHS
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infertility, Female, Microbial Colonization
Whether Vaginal Microbiota Affects Pregnancy Outcomes After Embryo Transfer
The goal of this observational study is to learn about vaginal microbial characteristics in the patients under in vitro fertilization treatment.
- Trial name
- NCT06296615
- Where
- China
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- ShangHai Ji Ai Genetics & IVF Institute
Syphilis
Interventions for Enhancing Adherence to Syphilis Treatment and Follow-up: Study Protocol for the Health Information and Monitoring of Sexually Transmitted Infections (SIM) Randomized Controlled Trial
The SIM study is a single-centre, randomized, controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance.
- Trial name
- SIM (NCT04753125)
- Testing
- follow-up by telephone, follow-up via a game in a smartphone app, conventional follow-up by a health professional
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Hospital Moinhos de Vento
HIV Infections
Behavioral, Clinical and Basic Science Studies of Non-occupational Post-exposure Prophylaxis ("PEP-2")
This is a randomized trial to compare the effect of standard versus enhanced risk reduction counseling on risk behavior incidence in individuals receiving PEP medications.
- Trial name
- PEP-2 (NCT00473018)
- Testing
- standard versus enhanced risk reduction counseling
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of California, San Francisco
HIV
Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption
Background: Human immunodeficiency virus (HIV) infects CD4 T cells. There is no cure for HIV. People with HIV need to take daily medications called antiretroviral therapy (ART) to control their infection.
- Trial name
- NCT05419024
- Testing
- Acute Treatment Interruption
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
HIV Infections
Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR
Antiretroviral Therapy (ART) naive subjects will be enrolled in this clinical research study to test the safety and tolerability of fosamprenavir with or without ritonavir in combination TRIZIVIR and COMBIVIR.
- Trial name
- NCT00043888
- Testing
- fosamprenavir, COMBIVIR, ritonavir
- Where
- 18 sites in United States, France and 1 more
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Cytomegalovirus Retinitis, HIV Infections
A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS
To provide information about the usefulness and safety of giving injections of ganciclovir (DHPG) for treating peripheral cytomegalovirus (CMV) retinitis.
- Trial name
- NCT00000688
- Testing
- Ganciclovir
- Where
- 22 sites in United States
- Volunteers
- 180 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS
Peer-driven Intervention to Seek, Test & Treat Heterosexuals at High Risk for HIV
Approximately 21% of HIV infections in the U.S. are undiagnosed, but only about 40% of all adults have been tested. Thus, late diagnosis of HIV is common, and, furthermore, treatment delays and disruptions are widespread.
- Trial name
- BCAP (NCT01607541)
- Testing
- BCAP peer-driven intervention (PDI), Control intervention
- Where
- United States
- Volunteers
- 3,400 people
- Sponsor
- New York University
Pneumonia, Pneumocystis Carinii, HIV Infections
A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral / Oral Trimethoprim - Sulfamethoxazole in the Treatment of Pneumocystis Carinii Pneumonia in AIDS
This is a randomized double-blinded controlled study comparing aerosolized pentamidine with trimethoprim plus sulfamethoxazole (TMP / PurposeX).
- Trial name
- NCT00002056
- Testing
- Pentamidine isethionate
- Where
- United States
- Sponsor
- LyphoMed
HIV Infections
Fuzeon (Enfuvirtide) Early Access Program for Patients With HIV-1 Infection
This study will determine the safety and tolerability of Fuzeon (enfuvirtide) used together with other treatments for HIV infection in patients with advanced HIV disease. Fuzeon is an antiretroviral drug.
- Trial name
- NCT00050856
- Testing
- Enfuvirtide T/20/Ro 29,9800, HIV-1 Infusion Inhibitor
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Virus, Opioid Use Disorder
Combined Injectable Treatment for HIV and OUD
This is study seeks to evaluate perspectives of a combined injectable treatment for HIV and OUD. Specifically, with the development of new long-acting medications such as cabotegravir co-administered with rilpivirine (CAB/RPV)…
- Trial name
- CHOICE (NCT05991622)
- Testing
- Combined LAI Treatment: Cabenuva and Sublocade
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Rhode Island Hospital
HIV Seropositivity, HIV Drug Resistance
Study of the Prevalence of Transmitted HIV-1 Resistance, Viral Diversity, and Cluster Identification in Patients at the Time of HIV-1 Diagnosis
The primary objective of the study is to determine the frequency of transmission of viruses carrying at least one antiretroviral resistance mutation in all participants newly diagnosed with HIV-1
- Conditions
- HIV Seropositivity, HIV Drug Resistance, HIV Infections
- Trial name
- PRINAVIH (NCT07146529)
- Volunteers
- 30,060 people
- Sponsor
- ANRS, Emerging Infectious Diseases
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.